Journal ArticleOPEN ACCESS

Properties of GLP-1 agonists and their use in type 2 diabetes

Prescriber (2016) 27(1) 43-46
DOI: 10.1002/psb.1430
4Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

There are currently four glucagon-like peptide-1 (GLP-1) receptor agonists licensed for use in the treatment of type 2 diabetes in the UK: dulaglutide, exenatide, liraglutide and lixisenatide. Steve Chaplin gives an overview of their indications, mode of administration and adverse effects, and Professor Stephen Bain discusses their current place in therapy.

Cite

CITATION STYLE

APA

Chaplin, S., & Bain, S. (2016). Properties of GLP-1 agonists and their use in type 2 diabetes. Prescriber, 27(1), 43–46. https://doi.org/10.1002/psb.1430

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free